TibaRay lands spot on Nasdaq Tower in Times Square

Silicon Valley medtech startup TibaRay was featured on the Nasdaq Tower in New York City today after being selected by Lehigh University’s Startup Academy. The moment highlights the company’s push to commercialize its Galactica precision radiation therapy platform and raise visibility ahead of broader cancer-care development.

Why it matters: - The Nasdaq Tower feature gives TibaRay a high-profile public stage as it works toward commercializing next-generation radiation therapy. - Radiation therapy is used in the treatment of nearly half of all cancer patients, so gains in precision, efficiency and patient comfort could affect a large patient base. - The company’s visibility may also help support investor interest in its current fundraising effort at Wefunder.

What happened: - TibaRay appeared on the Nasdaq Tower in New York City’s Times Square on July 29, 2026. - Lehigh University’s Startup Academy selected TibaRay for the billboard feature. - The company was recognized for its approach to advancing cancer treatment and its entrepreneurship focus.

The details: - TibaRay is a Silicon Valley medical technology company headquartered in Fremont, California. - The company was founded on Stanford University research. - TibaRay is developing Galactica, an upright linac radiation therapy platform. - Galactica is designed to improve patient comfort while delivering highly targeted cancer treatment in a smaller, more efficient system. - The platform is also intended to support future FLASH radiation therapy. - FLASH delivers radiation in less than a second and has shown potential to kill tumors while minimizing damage to surrounding healthy tissue. - CEO Thinh Tran said the milestone brings TibaRay closer to making the next generation of radiation therapy available to patients. - Tran said the company wants cancer treatment to be faster, more precise and more accessible. - TibaRay says its broader platform also supports commercial uses beyond cancer care.

Between the lines: - The Times Square placement signals that TibaRay is moving from research-driven development toward broader market awareness. - The company is tying its story to a familiar pain point in oncology: making radiation therapy more precise without adding burden for patients. - The combination of a startup academy selection and a public billboard suggests TibaRay is seeking both validation and momentum as it advances toward commercialization.

What's next: - TibaRay says it will continue advancing commercialization of its radiation therapy technologies. - The company says it will keep working to expand access to advanced cancer care and improve treatment outcomes. - Interested individuals can learn more about the company’s investment opportunity and product updates at TibaRay.